Rocket Pharmaceuticals, Inc. Warrant

Rocket Pharmaceuticals, Inc. is a multi-platform biotechnology company that develops gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs targeting Fanconi anemia, leukocyte adhesion deficiency-I, and pyruvate kinase deficiency. It also has a clinical-stage in vivo adeno-associated virus program for Danon disease. The company has license agreements with several research institutions and is headquartered in Cranbury, New Jersey.